These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38725780)

  • 21. Measuring Emicizumab Levels in the Hemostasis Laboratory.
    Kershaw G; Dix C
    Methods Mol Biol; 2023; 2663():589-595. PubMed ID: 37204738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
    Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
    EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
    Callaghan MU; Asikanius E; Lehle M; Oldenburg J; Mahlangu J; Uguen M; Chebon S; Kruse-Jarres R; Jiménez-Yuste V; Shima M; Trask P; Kempton CL; Kessler CM; Levy GG; Peyvandi F
    Res Pract Thromb Haemost; 2022 Aug; 6(6):e12782. PubMed ID: 36171959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
    Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
    Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Spontaneous disappearance of the inhibitor during emicizumab therapy in a patient with mild hemophilia A].
    Matsumoto A; Ogawa Y; Uchiyama Y; Ishikawa T; Naito C; Kobayashi N; Miyazawa Y; Ishizaki T; Inoue M; Moteki Y; Kitazawa S; Murakami M; Matsumoto N; Handa H
    Rinsho Ketsueki; 2022; 63(10):1392-1396. PubMed ID: 36351645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
    Hermans C; Ventriglia G; Obaji S; Beckermann BM; Lehle M; Catalani O; d'Oiron R; Frenzel L
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102239. PubMed ID: 38193069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes.
    Levy-Mendelovich S; Atia N; Budnik I; Barg AA; Avishai E; Cohen O; Brutman-Barazani T; Livnat T; Kenet G
    Res Pract Thromb Haemost; 2023 May; 7(4):100278. PubMed ID: 37538499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
    Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
    Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
    Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.